Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases

-- Expands Alexion’s metabolic franchise with the addition of Kanuma™ (sebelipase alfa) for LAL Deficiency (LAL-D) --
-- Launches of Kanuma and Alexion’s Strensiq™ (asfotase alfa) expected in 2015 --
-- Creates the most robust rare disease pipeline in biotech; adds SBC-103 for MPS IIIB to clinical development programs --
-- Combined pipeline to have eight highly innovative product candidates in the clinic for eleven indications --
-- Preclinical pipeline to have more than 30 diverse programs across a range of therapeutic modalities, including 12 from Synageva’s novel drug discovery platform, with at least four additional programs to enter the clinic in 2016 --

CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers

Combination Clinical Trial Data Showing Impressive Activity in Bone Cancer and Other Sarcomas
Administration was also found to be well tolerated in patients being treated with either aldoxorubicin plus gemcitabine or aldoxorubicin plus ifosfamide

LOS ANGELES, May 4, 2015 -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced an interim analysis from its two ongoing phase 1b aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas.  As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new weapon against chemotherapy resistant cancers.

Nektar Therapeutics Reports Financial Results for the First Quarter of 2015

SAN FRANCISCO, April 30, 2015  -- Nektar Therapeutics (NKTR) today reported its financial results for the first quarter ended March 31, 2015.

Cash and investments in marketable securities at March 31, 2015 were $325.8 million as compared to $262.8 million at December 31, 2014. Our cash and investments in marketable securities at March 31, 2015 includes a $100.0 million milestone payment received from AstraZeneca in Q1 2015 for the first commercial sale of Movantik™(naloxegol) in the U.S.